Nebulised furosemide in acute adult asthma

Yen, Zui-Shen; Chen, Shyr‐Chyr

doi:10.1136/emj.2005.028670

Cited by 10 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By an unknown mechanism it also decreases dyspnoea associated with both experimental conditions and terminal lung disease [36]. Furosemide is readily available, widely used, cheap and safe to be administered by nebuliser [37].…”

Section: Discussionmentioning

confidence: 99%

Furosemide in the Treatment of Phosgene Induced Acute Lung Injury

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Furosemide in the Treatment of Phosgene Induced Acute Lung Injury

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Other notable agents in this category include inhaled furosemide, 146,147 inhaled heparins, 148 colchicine, 149 and primarily as possible steroid-sparing agents, cyclosporine A, 150 mycophenolate, 151,152 methotrexate, 153,154 IVIG, 155,156 and gold. 157,158 Tumor necrosis factor-a antagonists Tumor necrosis factor-alpha (TNF-a) is an important cytokine in the innate immune response and has several possible roles in the pathogenesis of asthma.…”

Section: Miscellaneous Agentsmentioning

confidence: 99%

Novel Therapies in Asthma

Papierniak

Löwenthal

Harman

2013

American Journal of Therapeutics

View full text Add to dashboard Cite

Asthma is one of the most common conditions seen in clinical practice and carries both a significant disease burden in terms of patient morbidity and a high economic burden in both direct and indirect costs. Despite this, it remains a comparatively poorly understood disease, with only modest advances in treatment over the past decade. Corticosteroids remain the cornerstone of therapy. Both patient compliance with medications and physician adherence to evidence-based guidelines are often poor, and a high percentage of patients continue to have inadequately controlled disease even with optimal therapy. Following a contextual overview of the current treatment guidelines, this review focuses on novel asthma therapies, beginning with the introduction of the leukotriene receptor antagonist zafirlukast in the 1990s, continuing through advanced endoscopic therapy and into cytokine-directed biologic agents currently in development. Along with clinically relevant biochemistry and pharmacology, the evidence supporting the place of these therapies in current guidelines will be highlighted along with data comparing these agents with more conventional treatment. A brief discussion of other drugs, such as those developed for unrelated conditions and subsequently examined as potential asthma therapies, is included.

show abstract

“…49 Furosemid: Astımda nebülize furosemidin tedaviye eklenmesinin, relaksan prostaglandin indüksiyonu, inflamatuar hüc-relerden medyatör yapımını bloke ederek ve solunum epitelinde iyon değişimini düzenleyerek bronkodilatasyon yaptığı düşünülmektedir. 50 Magnezyum: Nebülize magnezyum tedavisinin, nebülize β-agonistle kullanıldığında, tek başına β-agonist tedavisine göre astımda bronkodilatasyon sağladığı düşünülmektedir. 51 İnhaler pulmoner hipertansiyon tedavisi Konjestif kalp yetmezliğine bağlı pulmoner hipertansiyonda, 20 ppm NO veya 2,5 µg/mL aerosolize iloprost kullanıldı-ğında düşme gözlenmektedir.…”

Section: Kısa Etkili Bronkodilatörler (Salbutamol)unclassified

Inhaled Therapy in Children

Pekcan¹

2012

Solunum

View full text Add to dashboard Cite

show abstract

Nebulised furosemide in acute adult asthma

Cited by 10 publications

References 2 publications

Furosemide in the Treatment of Phosgene Induced Acute Lung Injury

Furosemide in the Treatment of Phosgene Induced Acute Lung Injury

Novel Therapies in Asthma

Inhaled Therapy in Children

Contact Info

Product

Resources

About